Semaglutide Dosing Guide: mL Amounts & Personalized Dosing

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide dosing is measured in milligrams but prescribed as milliliter volumes, typically starting at 0.25 mg and titrating upward over four to sixteen weeks toward a target maintenance dose of 1.0 to 2.4 mg weekly. Dosing precision depends on the product concentration, body composition, baseline metabolic markers, and individual response patterns.

Knowing your exact mL-to-dose correspondence matters because improper titration or dose selection may affect efficacy and tolerability. PlexusDx supports precision-wellness approaches by considering biomarkers and genetic context—factors that may help inform a more individualized dosing strategy in partnership with your provider.

How Semaglutide Dosing Works: mL Amounts Across Strengths

Semaglutide is supplied at different concentrations: 1 mg/mL or 2.4 mg/mL formulations vary by product and pharmacy. A 0.25 mg starting dose from a 1 mg/mL vial equals 0.25 mL; the same dose from a 2.4 mg/mL concentrate equals approximately 0.1 mL. Always verify your vial concentration with your compounding pharmacy.

Standard titration schedules increase by 0.25 mg each week for four weeks, then jump to 0.5 mg, then 1.0 mg, then higher maintenance doses. Compounded semaglutide from licensed 503A pharmacies may use either concentration, so labeling clarity and pharmacist guidance are essential to prevent dosing errors.

Semaglutide Dose Escalation: Weekly mL Schedule and Timing Milestones

Most patients follow a four-week titration phase, stepping from 0.25 mg to 0.5 mg to 1.0 mg by week eight. Higher maintenance doses (1.7 or 2.4 mg) extend the titration over twelve to sixteen weeks. Slower titration may reduce gastrointestinal side effects and support better tolerability and adherence.

Week(s)	Typical Dose (mg)	mL at 1 mg/mL	mL at 2.4 mg/mL	Clinical Notes
1–4	0.25	0.25 mL	0.1 mL	Starting dose; assess tolerability
5–8	0.5	0.5 mL	0.21 mL	First escalation; monitor GI response
9–12	1.0	1.0 mL	0.42 mL	Standard maintenance for weight loss
13+	1.7–2.4	1.7–2.4 mL	0.71–1.0 mL	Higher maintenance; individualized adjustment

Individual Variation in Dosing Tolerance: Body Composition and Metabolic Baseline

Not all patients respond identically to the same dose. Body weight, baseline glucose, insulin resistance, and gastrointestinal sensitivity influence optimal dosing. A patient weighing 180 lbs may tolerate a 1.0 mg weekly dose well, while another at 220 lbs may require 1.7 mg or experience greater nausea at lower doses.

Biomarkers like fasting insulin, HbA1c, and liver function can reveal metabolic readiness for dose escalation. Patients with higher baseline insulin or signs of NAFLD may benefit from slower titration and closer provider monitoring. Discussing these markers with your provider before starting helps establish an individualized dosing baseline.

Safety, Provider Guidance, and Genetic Context in Dose Selection

GLP-1 receptor agonists carry established contraindications: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2, severe pancreatitis, or uncontrolled diabetic retinopathy. Your provider must rule out these conditions before dosing begins. Genetic variants in the GLP1R gene pathway may influence how your body processes and responds to semaglutide.

PlexusDx's Precision Peptide Genetic Test examines variants such as GLP1R rs6923761 and GIPR rs1800437, which relate to GLP-1 receptor signaling and may provide context about your genetic predisposition in GLP-1 pathways. This information should be interpreted with a qualified healthcare provider to inform personalized dosing conversations, not to predict exact medication response.

How PlexusDx Supports a More Personalized Approach

Genetic variants in GLP-1 receptor signaling pathways may help provide context for individual dosing variability. The Precision Peptide Genetic Test reveals predispositions in genes like GLP1R and GIPR, supporting more informed discussions with your provider about baseline expectations and potential titration strategies. This data should be interpreted as one factor among many.

The Precision Peptide Genetic Test does not predict your exact response to semaglutide or guarantee optimal dosing outcomes. Rather, it identifies genetic predispositions in peptide metabolism that can support a more personalized conversation with your qualified healthcare provider about your unique physiologic context and risk factors.

Understanding both your biomarkers and genetic context empowers a collaborative approach: you and your provider can use this information to design a dosing plan that aligns with your metabolic profile, tolerability, and health goals. PlexusDx compounded semaglutide ($149/mo) paired with genetic insights may help establish a more confidence-informed starting point.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.